Elevance Health, Inc. (ELV) earnings date, results and what the price requires
NYSE · SEC CIK 0001156039 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 15, 2026 | $50.47B | $1.46B | $6.71 | Filing |
| Mar 31, 2026 | Apr 22, 2026 | $50.18B | $1.76B | $8.00 | Filing |
| Dec 31, 2025 | Jan 28, 2026 | $49.75B | $547.0M | $2.56 | Filing |
| Sep 30, 2025 | Oct 21, 2025 | $50.71B | $1.19B | $5.32 | Filing |
| Jun 30, 2025 | Jul 17, 2025 | $49.78B | $1.74B | $7.72 | Filing |
| Mar 31, 2025 | Apr 17, 2025 | $48.89B | $2.18B | $9.61 | Filing |
| Dec 31, 2024 | Jan 23, 2025 | $45.44B | $418.0M | $1.88 | Filing |
| Sep 30, 2024 | Oct 17, 2024 | $45.11B | $1.02B | $4.36 | Filing |
What would Elevance Health, Inc. have to report for its valuation to change?
At $428.26, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 10.1% a year, to $36.61. On that path the next quarter needs diluted EPS near $5.86, against $5.32 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 10.1% | 10.1% |
| EPS needed in final year | $36.61 | $36.61 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ELV goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.